Featured stories 

 

10-25-2024 LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry® Trial (tralokinumab-ldrm) in Patients with Moderate-to-Severe Atopic Dermatitis (AD) at Fall Clinical 2024

 

10-23-2024 LEO Pharma Presents Adbry® (tralokinumab-ldrm) and Delgocitinib Cream Data at 2024 Fall Clinical Dermatology Conference

 

10-22-2024 LEO Pharma Launches Talk to the Hand Campaign to Raise Awareness of the Impact of Chronic Hand Eczema

 

09-25-2024 LEO Pharma Presents Late-Breaking Anzupgo® (delgocitinib) Cream Presentation at EADV 2024 Highlighting Results of Head-to-Head DELTA FORCE Trial in Chronic Hand Eczema (CHE)

 

09-25-2024 LEO Pharma Unveils Most Extensive EADV Program To Date with 5 Late Breaking Abstracts and 23 Posters Sharing Clinical and Real-World Data

 

09-23-2024 FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema

 

09-23-2024 European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE)

 

09-17-2024 Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S

 

08-21-2024 Timber Pharmaceuticals, Inc., a LEO Pharma Company, Provides an Update on the Development Program for TMB-001 in Congenital Ichthyosis

 

06-13-2024 FDA Approves Adbry® (tralokinumab-ldrm) Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)

 

06-11-2024 LEO Pharma presents new Real-World Evidence data at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference

 

3-10-2024 Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

 

3-9-2024 LEO Pharma Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial at the 2024 AAD Annual Meeting 

 

3-8-2024 LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data in Adults with Moderate-to-Severe Atopic Dermatitis at the 2024 AAD Annual Meeting 

 

3-6-24 LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas

 

12-15-23 LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years

 

8-21-23 LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical

 

3-18-23 LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

 

3-18-23 LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

 

3-17-23 LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting

 

10-26-22 LEO Pharma announces British Journal of Dermatology publication of Adbry™ (tralokinumab-ldrm) pooled safety data in moderate-to-severe atopic dermatitis

 

9-8-22 LEO Pharma presents new Adbry™ (tralokinumab-ldrm) safety data in moderate-to-severe atopic dermatitis at 31^st EADV Congress

 

8-25-22 LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

 

7-20-22 LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology

 

4-11-22 LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD Conference

 

3-25-22 LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting

 

2-17-22 LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States

 

12-28-21 LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

 

10-22-21 Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis

 

9-30-21 LEO Pharma presents interim data from Phase 3 tralokinumab long-term extension trial in moderate-to-severe atopic dermatitis at EADV 30th Congress

 

4-29-21 Update on U.S. FDA review of LEO Pharma’s Biologics License Application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis

 

4-23-21 LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021

 

4-23-21 LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults with Moderate-to-severe Atopic Dermatitis

 

10-29-20 LEO Pharma announces positive results of Phase 2b dose-finding study with delgocitinib cream in adult patients with mild-to-severe chronic hand eczema (CHE)

 

10-29-20 LEO Pharma Presents Data for Tralokinumab on Pooled Safety, S. aureus Colonization Reduction and Impact on Vaccine Response Rates at the 29th Annual European Academy of Dermatology and Venereology (EADV) Virtual Congress

 

10-27-20 LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020

 

10-22-20 LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment

 

10-16-20 LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab, Demonstrating Safety and Sustained Improvements in Severity and Quality of Life Measures in Adults with Moderate-to-Severe Atopic Dermatitis

 

8-4-20 LEO Pharma announces U.S. Food and Drug Administration Fast Track designation for delgocitinib cream for the treatment of adults with moderate-to-severe chronic hand eczema

MAT-56201 April 2022